Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial …

The aim of this systematic review was to answer the question: What are the treatments
available for bisphosphonate-related osteonecrosis of the jaws (BRONJ) and their …

PURPOSE To provide guidance regarding best practices in the prevention and
management of medicationrelated osteonecrosis of the jaw (MRONJ) in patients with …

Background Osteonecrosis of the jaw (ONJ) has been reported in patients receiving
bisphosphonates for metastatic bone disease. ONJ incidence, risk factors, and outcomes …

American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related
Osteonecrosis of the Jaws—2009 Update - Journal of Oral and Maxillofacial Surgery Skip to …

Background A single infusion of intravenous zoledronic acid decreases bone turnover and
improves bone density at 12 months in postmenopausal women with osteoporosis. We …

ONJ has been increasingly suspected to be a potential complication of bisphosphonate
therapy in recent years. Thus, the ASBMR leadership appointed a multidisciplinary task …

Background Bisphosphonates are specific inhibitors of osteoclastic activity and used in the
treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be …

Osteonecrosis of the jaw (ONJ) is a complication of high-dose bisphosphonate use,
characterized by the finding of exposed bone in the oral cavity. It has been assumed that the …

PURPOSE: Bisphosphonates (BPs) are a widely used class of drugs that are effective in the
treatment and prevention of osteoporosis, hypercalcemia of malignancy, and bone …